×
About 780 results

ALLMedicine™ Gastrointestinal Tumors Center

Research & Reviews  266 results

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Clinical Trial of Autologous Tcm Immunotherapy in ICC
https://clinicaltrials.gov/ct2/show/NCT03820310

Apr 26th, 2022 - Intrahepatic cholangiocarcinoma (ICC) accounts for 2%~3% of gastrointestinal tumors, and the incidence has been on the rise globally. The pathogenesis of ICC remains unclearly. Compared with palliative resection, the postoperative survival rate of...

TROP2 Down-Regulated DSG2 to Promote Gastric Cancer Cell Invasion and Migration by EGFR...
https://doi.org/10.2174/1568009622666220407111013
Current Cancer Drug Targets; Yang T, Jia L et. al.

Apr 9th, 2022 - Explore the specific mechanism of TROP2 in promoting cancer in gastric cancer, and provide a basis for the prevention and treatment of gastric cancer. Background Gastric cancer (GC) is the fourth most commonly found cancer and the second highest c...

Long non-coding RNA LINC01123 promotes cell proliferation, migration and invasion via i...
https://doi.org/10.1016/j.prp.2022.153843
Pathology, Research and Practice; Liu Z, Ma L et. al.

Mar 25th, 2022 - Increasing evidences demonstrated that long non-coding RNAs (lncRNAs) participates in the occurrence and development of cancer. In this study, we explored the function and molecular mechanism of LINC01123 in colorectal cancer progression. Analyze ...

see more →

Guidelines  1 results

Endoscopic resection of superficial gastrointestinal tumors.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977951
World Journal of Gastroenterology; Marc G, Lopes CV

Aug 14th, 2008 - Therapeutic endoscopy plays a major role in the management of gastrointestinal (GI) neoplasia. Its indications can be generalized into four broad categories; to remove or obliterate neoplastic lesion, to palliate malignant obstruction, or to treat...

see more →

Drugs  5 results see all →

Clinicaltrials.gov  19 results

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Clinical Trial of Autologous Tcm Immunotherapy in ICC
https://clinicaltrials.gov/ct2/show/NCT03820310

Apr 26th, 2022 - Intrahepatic cholangiocarcinoma (ICC) accounts for 2%~3% of gastrointestinal tumors, and the incidence has been on the rise globally. The pathogenesis of ICC remains unclearly. Compared with palliative resection, the postoperative survival rate of...

Tongue Image Database and Diagnostic Model for Digestive Tract Disease Diagnosis
https://clinicaltrials.gov/ct2/show/NCT05182983

Jan 10th, 2022 - The tongue images of patients with gastrointestinal diseases and healthy people will be collected and the tongue image database will be established. Through deep learning and artificial intelligence, early screening models of various gastrointesti...

CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors
https://clinicaltrials.gov/ct2/show/NCT04883970

Jun 4th, 2021 - The objective of the study is to constrcut a noninvasive approach 124I-18B10(10L) PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from CLDN18.2 targeting treatm...

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
https://clinicaltrials.gov/ct2/show/NCT04612712

Mar 29th, 2021 - The study consists of dose escalation and dose expansion. The preset dose of Donafenib is 50 mg BID, 100 mg BID and 200 mg BID, and the preset dose of KN046 is 5 mg/kg Q3W. Dose expansion will enroll subjects who with advanced hepatocellular carci...

see more →

News  21 results

Average Cumulative Relative Adjuvant Chemo Dose Linked With Survival in CRC
https://www.onclive.com/view/average-cumulative-relative-adjuvant-chemo-dose-linked-with-survival-in-crc

Aug 17th, 2021 - Average cumulative relative dose (ACRD) was found to be associated with survival over average relative dose intensity (ARDI) in patients with colorectal cancer (CRC), highlighting that obese patients receive lower cumulative doses of adjuvant chem...

Optimal Approach Toward Advanced Gastric Cancers in US
https://www.onclive.com/view/optimal-approach-toward-advanced-gastric-cancers-in-us

Apr 2nd, 2021 - Johanna Bendell, MD: In Japan, there are screening protocols that catch these cancers early so they can be cured before they get to an advanced setting. Here in the United States, we don’t have that so much. How are we trying to work to look at ea...

The Evolving Story of Mutational Landscape in Cancer and Its Implications: Bad Luck or Great Hope?
https://www.onclive.com/view/the-evolving-story-of-mutational-landscape-in-cancer-and-its-implications-bad-luck-or-great-hope

Dec 20th, 2020 - Andre Goy, MD Editor-in-Chief of Oncology & Biotech News Chairman and Director Chief of Lymphoma Director, Clinical and Translational Cancer Research John Theurer Cancer Center at Hackensack University Medical Center While it is...

Survival Benefit Observed With Cetuximab in RAS Wild-Type Colorectal Cancer
https://www.onclive.com/view/survival-benefit-observed-with-cetuximab--in-ras-wild-type-colorectal-cancer

Dec 20th, 2020 - Volker Heinemann, MD, PhD Cetuximab (Erbitux) plus FOLFIRI may offer a survival advantage over FOLFIRI plus bevacizumab (Avastin) in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer who do not have RAS mu...

Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer
https://www.onclive.com/view/regorafenib-extends-pfs-in-locally-advanced-biliary-tract-cancer

Dec 20th, 2020 - The oral multi-kinase inhibitor regorafenib extended progression-free survival (PFS) in patients with metastatic or unresectable biliary tract cancer (BTC) who were previously treated with gemcitabine (Gemzar) and a platinum-based chemotherapy, ac...

see more →